21 research outputs found
Investigation of genetics and genomics in asthma
Asthma is the most common disease of childhood in the westernised world, affecting one child in seven in the United Kingdom alone. It is a complex disease involving both genetic and environmental factors. The financial burden for sufferers approximates £1 billion per annum in the UK and 80% of the sum is attributable to the patients with the severe, “difficult/therapy-resistant” form of the disease. Previously, a Genome Wide Association Study (GWAS) for childhood asthma identified a number of loci significantly associated to the disease. The top ten SNP hits with the highest association (0.0001>P>0.00001) were chosen for an investigation of their importance in cases of severe asthma, both childhood and adult. The 10 SNPs were genotyped in 397 adults and 94 children using TaqMan® SNP Genotyping Assays. Genotyping data was analysed for genetic associations to the severe asthma phenotype using chi-squared tests. Control data was obtained from data generated in the original GWAS for the British controls. SNP rs6585018 located in the PDCD4 gene predicted promoter was found to be significantly associated to childhood asthma (P=3.4x10-7). Additional markers on the PDCD4 gene area were chosen to be typed in 116 severe asthmatic children and 145 healthy children from the UK. SNPs rs6585018 (P=0.005), rs1322997 (P=0.005) in the predicted promoter area and rs34104444 (P=0.01) in exon 5 were associated to severe asthma. The three SNPs were also correlated with PDCD4 transcript levels. PDCD4 genomic area was analysed in silico and ElectroMobility Shift Assay (EMSA) experiments were designed for the rs6548018 alleles to examine how they alter transcription factor binding sites. SNP rs6585018 was found to alter the binding site of the Myb transcription factor possibly altering the expression of PDCD4 gene. This study has provided insights into the genetic factors that are involved in disease aetiology of severe asthma
Time of Lactation and Maternal Fucosyltransferase Genetic Polymorphisms Determine the Variability in Human Milk Oligosaccharides
Rationale: Human milk oligosaccharides (HMOs) vary among mothers and genetic
factors contribute to this variability.We assessed changes in HMO concentrations during
the first year of lactation and the relationship with FUT2 Secretor group and FUT3 Lewis
group defining genetic polymorphisms.
Methods: Milk samples were collected from lactating mothers participating in the LIFE
Child cohort in Leipzig, Germany. The concentrations of 24 HMOs in milk samples
collected at 3 months (N = 156), 6 months (N = 122), and 12 months (N = 28) were
measured using liquid chromatography. Concentrations of HMOs were compared at all
time-points and were tested for their associations with FUT2 and FUT3 genetic variations
by sPLS regression.
Results: FUT2 SNP rs601338 was found to predominantly define the Secretor status
Se-: 11.8% and it was highly correlated with 2′-fucosyllactose (2′FL, p < 0.001)
and lacto-N-fucosylpentaose-I (LNFP-I, p < 0.001). FUT3 SNPs rs28362459 and
rs812936 were found to define Lewis status (Le-: 5.9%) and correlated with
lacto-N-fucosylpentaose-II (LNFP-II, p < 0.001). A polygenic score predicted the
abundance of 2′FL levels within Secretors’ milk (adj. R2 = 0.58, p < 0.001). Mean
concentrations of most of the individual HMOs, as well as the sums of the measured
HMOs, the fucosylated HMOs, and the neutral HMOs were lower at 6 and 12 months
compared to 3 months (p < 0.001).
Conclusions: Secretor and Lewis status defined by specific FUT2 and FUT3 SNPs are
confirmed to be good proxies for specific individual HMOs and milk group variabilities.
The polygenic score developed here is an opportunity for clinicians to predict 2′FL
levels in milk of future mothers. These results show opportunities to strengthen our
understanding of factors controlling FUT2 and FUT3 functionality, the temporal changes
and variability of HMO composition during lactation and eventually their significance for
infant development
Recommended from our members
A Polymorphism Affecting MYB Binding within the Promoter of the PDCD4 Gene is Associated with Severe Asthma in Children
A previous genome-wide association study in asthma revealed putative associations that merit further investigation. In this study, the genome-wide significant associations of SNPs at the 5% false discovery rate were examined in independent groups of severe asthmatics. The panel consisted of 397 severe asthmatic adults, 116 severe asthmatic children, and a collection of 207 family-trios with an asthmatic proband. Three SNPs in the PDCD4 gene (rs6585018:G>A, rs1322997:C>A, and rs34104444:G>A) were significantly associated with severe childhood asthma (P values: 0.003, 0.002, 0.004) and total immunoglobulin E (IgE) levels (P values: 0.034, 0.041, 0.052). In an independent group of 234 asthmatic children and 652 controls, PDCD4 SNPs rs1407696:T>G and rs11195360:T>C were associated with total IgE levels (P values: 0.006, 0.014). In silico analysis of PDCD4 locus showed that rs6585018:G>A had the potential to affect MYB transcription factor binding, shown to act as a PDCD4-transcription inducer. Electromobility shift assays and reporter assays revealed that rs6585018:G>A alters MYB binding thereby influencing the expression of PDCD4. SNPs within MYB itself confer susceptibility to eosinophilia and asthma. Our association between a variant MYB binding site in PDCD4 and the severest form of childhood asthma therefore suggests that PDCD4 is a novel molecule of importance to asthmatic inflammatory responses
Improvement of cardiometabolic markers after fish oil intervention in young Mexican adults and the role of PPARα L162V and PPARγ2 P12A
Polyunsaturated fatty acids (PUFA) contained in fish oil (FO) are ligands for peroxisome proliferator-activated receptors (PPAR) that may induce changes in cardiometabolic markers. Variation in PPAR genes may influence the beneficial responses linked to FO supplementation in young adults. The study aimed to analyze the effect of FO supplementation on glucose metabolism, circulating lipids and inflammation according to PPARα L162V and PPARγ2 P12A genotypes in young Mexican adults. 191 young, non-smoking subjects between 18 and 40 years were included in a one-arm study. Participants were supplemented with 2.7 g/day of EPA+DHA, during six weeks. Dietary analysis, body composition measurements and indicators for glucose metabolism, circulating lipids, and markers for inflammation were analyzed before and after intervention. An overall decrease in triglycerides (TG) and an increase in HS-ω3 index were observed in all subjects [-4.1 mg/dL, (SD:±51.7), P=.02 and 2.6%, (SD:±1.2), P\u3c.001 respectively]. Mean fasting insulin and glycated hemoglobin (HbA1c%) were significantly decreased in all subjects [-0.547mlU/L, (SD:±10.29), P=.034 and-0.07%, (SD:±0.3), P\u3c.001 respectively], whereas there was no change in body composition, fasting glucose, adiponectin and inflammatory markers. Subjects carrying the minor alleles of PPARα L162V and PPARγ2 P12A had higher responses in reduction of TG and fasting insulin respectively. Interestingly, doses below 2.7 g/day (1.8 g/day) were sufficient to induce a significant reduction in fasting insulin and HbA1c% from baseline (P=.019 and P\u3c.001). The observed responses in triglycerides and fasting insulin in the Mexican population give further evidence of the importance of FO supplementation in young people as an early step towards the prevention of cardiometabolic disease.
Trial registration: ClinicalTrials.gov NCT02296385
An epigenome-wide association study of total serum immunoglobulin E concentration
Immunoglobulin E (IgE) is a central mediator of allergic (atopic) inflammation. Therapies directed against IgE can alleviate hay fever and allergic asthma. Genetic association studies have not yet identified novel therapeutic targets or pathways underlying IgE regulation. We therefore surveyed epigenetic associations between serum IgE concentrations and methylation at loci concentrated in CpG islands genome wide in 95 nuclear pedigrees, using DNA from peripheral blood leukocytes. We validated positive results in additional families and in subjects from the general population. Here we show replicated associations-with a meta-analysis false discovery rate less than 10(-4)-between IgE and low methylation at 36 loci. Genes annotated to these loci encode known eosinophil products, and also implicate phospholipid inflammatory mediators, specific transcription factors and mitochondrial proteins. We confirmed that methylation at these loci differed significantly in isolated eosinophils from subjects with and without asthma and high IgE levels. The top three loci accounted for 13% of IgE variation in the primary subject panel, explaining the tenfold higher variance found compared with that derived from large single-nucleotide polymorphism genome-wide association studies. This study identifies novel therapeutic targets and biomarkers for patient stratification for allergic diseases
Do human milk oligosaccharides protect against infant atopic disorders and food allergy?
Atopic disorders (AD), often coexistent with food allergy (FA), start developing in early life and have lifelong health consequences. Breastfeeding is thought to be protective against AD and FA, but the data are controversial, and mechanisms are not well understood. Human milk oligosaccharides (HMOs) are complex carbohydrates that are abundant in human milk. These are thought to contribute to the development of the infant immune system by (i) promoting healthy microbiome, (ii) inhibiting pathogen binding to gut mucosa and (iii) modulating the immune system. Differences in microbiome composition between allergic and healthy infants have been observed, regardless of breastfeeding history. To date, limited studies have examined the preventive effects of HMOs on AD and FA in infants and current data relies on observation studies as trials of varying HMO intake through randomising individuals to breastfeeding are unethical. There is evidence for beneficial effects of breastfeeding on lowering the risks of FA, eczema and asthma but there are inconsistencies amongst studies in the duration of breastfeeding, diagnostic criteria for AD and the age at which the outcome was assessed. Furthermore, current analytical methods primarily used today only allow detection of 16–20 major HMOs while more than 100 types have been identified. More large-scale longitudinal studies are required to investigate the role of HMO composition and the impact of changes over the lactation period in preventing AD and FA later in lif
Concentrations of oligosaccharides in human milk and child growth
Background!#!The relationship between human milk oligosaccharides (HMO) and child growth has been investigated only insufficiently with ambiguous results. Therefore, this study examines potential influencing factors of HMO concentrations and how HMO are associated with child growth parameters.!##!Methods!#!Milk samples from the German LIFE Child cohort of healthy children were analyzed for 9 HMO. Putative associations with maternal and child cofactors and child height, head circumference and BMI between 3 months and 7 years of age were examined. Secretor status, defined as the presence of 2'-fucosyllactose, was investigated for associations with infant outcomes.!##!Results!#!Our population consisted of 21 (14.7%) non-secretor and 122 (85.3%) secretor mothers. Maternal age was significantly associated with higher 3'SL concentrations; gestational age was associated with LNT, 6'SL and LNFP-I. Pre-pregnancy BMI was negatively associated with LNnT only in non-secretors. The growth velocity of non-secretors' children was inversely associated with LNnT at 3 months to 1 year (R = 0.95 [0.90, 0.99], p = 0.014), 1 to 2 years (R = 0.80 [0.72, 0.88], p &lt; 0.001) and 5 to 6 years (R = 0.71 [0.57, 0.87], p = 0.002). 2'FL was negatively associated with BMI consistently, reaching statistical significance at 3 months and 4 and 5 years. Children of non-secretors showed higher BMI at 3 months, 6 months, and 3, 6, and 7 years of age.!##!Conclusion!#!We found that some associations between HMO and infant growth may extend beyond the infancy and breastfeeding periods. They highlight the importance of both maternal and infant parameters in the understanding of the underlying associations.!##!Trial registration!#!The study is registered with ClinicalTrial.gov: NCT02550236
Time of Lactation and Maternal Fucosyltransferase Genetic Polymorphisms Determine the Variability in Human Milk Oligosaccharides
Rationale: Human milk oligosaccharides (HMOs) vary among mothers and genetic
factors contribute to this variability.We assessed changes in HMO concentrations during
the first year of lactation and the relationship with FUT2 Secretor group and FUT3 Lewis
group defining genetic polymorphisms.
Methods: Milk samples were collected from lactating mothers participating in the LIFE
Child cohort in Leipzig, Germany. The concentrations of 24 HMOs in milk samples
collected at 3 months (N = 156), 6 months (N = 122), and 12 months (N = 28) were
measured using liquid chromatography. Concentrations of HMOs were compared at all
time-points and were tested for their associations with FUT2 and FUT3 genetic variations
by sPLS regression.
Results: FUT2 SNP rs601338 was found to predominantly define the Secretor status
Se-: 11.8% and it was highly correlated with 2′-fucosyllactose (2′FL, p < 0.001)
and lacto-N-fucosylpentaose-I (LNFP-I, p < 0.001). FUT3 SNPs rs28362459 and
rs812936 were found to define Lewis status (Le-: 5.9%) and correlated with
lacto-N-fucosylpentaose-II (LNFP-II, p < 0.001). A polygenic score predicted the
abundance of 2′FL levels within Secretors’ milk (adj. R2 = 0.58, p < 0.001). Mean
concentrations of most of the individual HMOs, as well as the sums of the measured
HMOs, the fucosylated HMOs, and the neutral HMOs were lower at 6 and 12 months
compared to 3 months (p < 0.001).
Conclusions: Secretor and Lewis status defined by specific FUT2 and FUT3 SNPs are
confirmed to be good proxies for specific individual HMOs and milk group variabilities.
The polygenic score developed here is an opportunity for clinicians to predict 2′FL
levels in milk of future mothers. These results show opportunities to strengthen our
understanding of factors controlling FUT2 and FUT3 functionality, the temporal changes
and variability of HMO composition during lactation and eventually their significance for
infant development
Genetic Risk Score Predictive of the Plasma Triglyceride Response to an Omega-3 Fatty Acid Supplementation in a Mexican Population
Our group built a genetic risk score (GRS) of the plasma triglyceride (TG) response to an omega-3 (n-3) fatty acid (FA) supplementation in Caucasian Canadians that explained 21.53% of the TG variance. The objective was to refine the GRS by fine mapping and to test its association with the TG response in young Mexican adults. A total of 191 participants underwent a 6-week n-3 FA supplementation providing 2.7g/day of docosahexaenoic and eicosapentaenoic acids. Using quantitative polymerase chain reaction (PCR), 103 single-nucleotide polymorphisms (SNPs) were genotyped. A stepwise regression adjusted for age, sex, and body mass index (BMI) was used to select the strongest SNPs to include in the genetic risk model. A GRS was calculated from the sum of at-risk alleles. The contribution of the GRS to the TG response was assessed by ANCOVA with age, sex, and BMI included in the model. Several differences in allele frequency were observed between Canadians and Mexicans. Five lead SNPs were included in the genetic risk model, in which the GRS accounted for 11.01% of the variance of the TG response (p < 0.0001). These findings highlight the important contribution of genetic factors to the heterogeneity of the TG response to an n-3 FA supplementation among Mexicans
Time of Lactation and Maternal Fucosyltransferase Genetic Polymorphisms Determine the Variability in Human Milk Oligosaccharides
Rationale: Human milk oligosaccharides (HMOs) vary among mothers and genetic
factors contribute to this variability.We assessed changes in HMO concentrations during
the first year of lactation and the relationship with FUT2 Secretor group and FUT3 Lewis
group defining genetic polymorphisms.
Methods: Milk samples were collected from lactating mothers participating in the LIFE
Child cohort in Leipzig, Germany. The concentrations of 24 HMOs in milk samples
collected at 3 months (N = 156), 6 months (N = 122), and 12 months (N = 28) were
measured using liquid chromatography. Concentrations of HMOs were compared at all
time-points and were tested for their associations with FUT2 and FUT3 genetic variations
by sPLS regression.
Results: FUT2 SNP rs601338 was found to predominantly define the Secretor status
Se-: 11.8% and it was highly correlated with 2′-fucosyllactose (2′FL, p < 0.001)
and lacto-N-fucosylpentaose-I (LNFP-I, p < 0.001). FUT3 SNPs rs28362459 and
rs812936 were found to define Lewis status (Le-: 5.9%) and correlated with
lacto-N-fucosylpentaose-II (LNFP-II, p < 0.001). A polygenic score predicted the
abundance of 2′FL levels within Secretors’ milk (adj. R2 = 0.58, p < 0.001). Mean
concentrations of most of the individual HMOs, as well as the sums of the measured
HMOs, the fucosylated HMOs, and the neutral HMOs were lower at 6 and 12 months
compared to 3 months (p < 0.001).
Conclusions: Secretor and Lewis status defined by specific FUT2 and FUT3 SNPs are
confirmed to be good proxies for specific individual HMOs and milk group variabilities.
The polygenic score developed here is an opportunity for clinicians to predict 2′FL
levels in milk of future mothers. These results show opportunities to strengthen our
understanding of factors controlling FUT2 and FUT3 functionality, the temporal changes
and variability of HMO composition during lactation and eventually their significance for
infant development